Literature DB >> 3855866

Heterogeneity of clonogenic cells in acute myeloblastic leukemia.

K D Sabbath, E D Ball, P Larcom, R B Davis, J D Griffin.   

Abstract

The expression of differentiation-associated surface antigens by the clonogenic leukemic cells from 20 patients with acute myeloblastic leukemia (AML) was studied with a panel of seven cytotoxic monoclonal antibodies (anti-Ia, -MY9, -PM-81, -AML-2-23, -Mol, -Mo2, and -MY3). The surface antigen phenotypes of the clonogenic cells were compared with the phenotypes of the whole leukemic cell population, and with the phenotypes of normal hematopoietic progenitor cells. In each case the clonogenic leukemic cells were found within a distinct subpopulation that was less "differentiated" than the total cell population. Clonogenic leukemic cells from different patients could be divided into three phenotype groups. In the first group (7 of 20 cases), the clonogenic cells expressed surface antigens characteristic of the normal multipotent colony-forming cell (Ia, MY9). These cases tended to have "undifferentiated" (FAB M1) morphology, and the total cell population generally lacked expression of "late" monocyte antigens such as MY3 and Mo2. A second group (seven cases) of clonogenic cells expressed surface antigens characteristic of an "early" (day 14) colony-forming unit granulocyte-monocyte (CFU-GM), and a third group (six cases) was characteristic of a "late" (day 7) CFU-GM. The cases in these latter two groups tended to have myelomonocytic (FAB M4) morphology and to express monocyte surface antigens. These results suggest that the clonogenic cells are a distinct subpopulation in all cases of AML, and may be derived from normal hematopoietic progenitor cells at multiple points in the differentiation pathway. The results further support the possibility that selected monoclonal antibodies have the potential to purge leukemic clonogenic cells from bone marrow in some AML patients without eliminating critical normal progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3855866      PMCID: PMC423572          DOI: 10.1172/JCI111756

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Human cell lines that elaborate colon-stimulating activity for the marrow cells of man and other species.

Authors:  J F Di Persio; J K Brennan; M A Lichtman; B L Speiser
Journal:  Blood       Date:  1978-03       Impact factor: 22.113

2.  Granuloerythropoietic colonies in human bone marrow, peripheral blood, and cord blood.

Authors:  A A Fauser; H A Messner
Journal:  Blood       Date:  1978-12       Impact factor: 22.113

3.  PHA-induced colony formation in acute non-lymphocytic and chronic myeloid leukemia.

Authors:  B Löwenberg; K Swart; A Hagemeijer
Journal:  Leuk Res       Date:  1980       Impact factor: 3.156

4.  HLA-A2 as a target for cell-mediated lympholysis: evidence from immunoselected HLA-A2 negative mutant cell lines.

Authors:  P E Andreotti; J R Apgar; P Cresswell
Journal:  Hum Immunol       Date:  1980-07       Impact factor: 2.850

5.  Self-renewal in culture of proliferative blast progenitor cells in acute myeloblastic leukemia.

Authors:  R N Buick; M D Minden; E A McCulloch
Journal:  Blood       Date:  1979-07       Impact factor: 22.113

6.  Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia.

Authors:  R Gallagher; S Collins; J Trujillo; K McCredie; M Ahearn; S Tsai; R Metzgar; G Aulakh; R Ting; F Ruscetti; R Gallo
Journal:  Blood       Date:  1979-09       Impact factor: 22.113

7.  Proliferative state of blast cell progenitors in acute myeloblastic leukemia (AML).

Authors:  M D Minden; J E Till; E A McCulloch
Journal:  Blood       Date:  1978-09       Impact factor: 22.113

8.  Comparison between agar and methylcellulose cultures of human leukemic cells.

Authors:  K Kubota; H D Preisler; K Sagawa; J Minowada
Journal:  Cancer Res       Date:  1981-08       Impact factor: 12.701

9.  Antigens on human monocytes identified by monoclonal antibodies.

Authors:  R F Todd; L M Nadler; S F Schlossman
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

10.  Acute nonlymphocytic leukemia: heterogeneity of stem cell origin.

Authors:  P J Fialkow; J W Singer; J W Adamson; K Vaidya; L W Dow; J Ochs; J W Moohr
Journal:  Blood       Date:  1981-06       Impact factor: 22.113

View more
  25 in total

1.  Identification and purification of human erythroid progenitor cells by monoclonal antibody to the transferrin receptor (TU 67).

Authors:  F Herrmann; J D Griffin; K D Sabbath; W Oster; P Wernet; R Mertelsmann
Journal:  Blut       Date:  1988-04

Review 2.  Bone marrow purging using monoclonal antibodies.

Authors:  N K Ramsay; J H Kersey
Journal:  J Clin Immunol       Date:  1988-03       Impact factor: 8.317

Review 3.  What happened to anti-CD33 therapy for acute myeloid leukemia?

Authors:  Joseph G Jurcic
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

4.  Differentiation of the rat myelomonocytic leukemia cell line c-WRT-7 by in vitro culture with the rat bone marrow preadipocyte cell line REC A16.

Authors:  T Tanaka; S Okamura; S Yasumoto; N Takeichi; H Kobayashi; Y Niho
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 5.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

6.  Initial blood fetal hemoglobin concentration is elevated and is associated wtih prognosis in children with acute lymphoid or myeloid leukemia.

Authors:  J Rautonen; M A Siimes
Journal:  Blut       Date:  1990-07

7.  Recognition of binding sites on Candida albicans by monoclonal antibodies to human leukocyte antigens.

Authors:  C L Mayer; R D Diamond; J E Edwards
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

Review 8.  The therapeutic promise of the cancer stem cell concept.

Authors:  Natasha Y Frank; Tobias Schatton; Markus H Frank
Journal:  J Clin Invest       Date:  2010-01       Impact factor: 14.808

Review 9.  Identification and targeting of cancer stem cells.

Authors:  Tobias Schatton; Natasha Y Frank; Markus H Frank
Journal:  Bioessays       Date:  2009-10       Impact factor: 4.345

10.  The phenotype of L-CFU and its correlation with the immunological characteristics of the blast cell population in AML.

Authors:  M C del Cañizo; J Almeida; J F San Miguel; A Orfao; M Gonzalez; A Lopez Borrasca
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.